← ANALYST RATINGS · TIPRANKS

Vera Therapeutics (VERA): analyst forecast and price target

$27.88 −2.42% close 16.10.26 · market cap $2.1B · Healthcare · Biotechnology IWM 0.06%
Price targets and ratings of

Analyst consensus

Strong Buy

8 Buy1 Hold0 Sell

Ratings of 9 analysts in the last 3 months · top analysts only

12-month forecast

$76.86+175.7% upside

Based on 9 price targets given in the last 3 months, the average target is $76.86, the highest $100, the lowest $34.00. The average is +175.7% from the last price of $27.88.

$25.00$50.00$75.00$100Jan 26AprJulOctJan 27AprJulOctHigh$100Average$76.86Low$34.00
Highest target $100 Average target $76.86 Lowest target $34.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% Wells Fargo $70.00 Buy +151.1% Reiterated 15.10.26on TipRanks 07:40 +6.6%next day −1.3%
Unknown Analyst Leerink Partners $34.00 Hold +22.0% Initiated 12.10.26on TipRanks Oct 13 12:05 −7.2%next day −3.3%
Dina Ramadane★★★★★★★★★★#5584 · hits 75% · avg +7.8% Bank of America Securities $66.00 → $60.00−9.1% Buy +115.2% Reiterated 09.10.26on TipRanks 06:55 −0.1%next day −7.2% · 5 days −4.7%
Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% H.C. Wainwright $90.00 Buy +222.8% Reiterated 01.10.26on TipRanks 10:35 −4.2%next day −2.6% · 5 days −5.4%
Unknown Analyst Jefferies $59.00 Buy +111.6% Reiterated 16.09.26on TipRanks Sep 23 21:00 −5.2%next day +6.7% · 5 days +2.0%
Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% Wedbush $34.00 Hold +22.0% Reiterated 16.09.26on TipRanks 08:09 −5.2%next day +6.7% · 5 days +2.0%
Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% J.P. Morgan — Buy — Reiterated 15.09.26on TipRanks Sep 16 07:06 −0.7%next day −5.2% · 5 days +5.3%
Dina Ramadane★★★★★★★★★★#5584 · hits 75% · avg +7.8% Bank of America Securities $66.00 Buy +136.7% Reiterated 15.09.26on TipRanks Sep 16 04:55 −0.7%next day −5.2% · 5 days +5.3%
Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% Wells Fargo $70.00 Buy +151.1% Reiterated 15.09.26on TipRanks Sep 16 04:50 −0.7%next day −5.2% · 5 days +5.3%
Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% LifeSci Capital $90.00 Buy +222.8% Reiterated 15.09.26on TipRanks 11:25 −0.7%next day −5.2% · 5 days +5.3%
Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% Raymond James — Buy — Reiterated 15.09.26on TipRanks 10:15 −0.7%next day −5.2% · 5 days +5.3%
Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% TD Cowen $78.00 Buy +179.8% Reiterated 31.08.26on TipRanks 10:50 0.0%next day +1.1% · 5 days +3.7%
Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% Guggenheim $76.00 Buy +172.6% Reiterated 14.08.26on TipRanks Aug 17 07:32 +9.7%next day +0.5% · 5 days +3.4%
Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% H.C. Wainwright $125 → $90.00−28.0% Buy +222.8% Reiterated 12.08.26on TipRanks 06:30 −1.2%next day −4.4% · 5 days +8.1%
Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% Cantor Fitzgerald $100 Buy +258.7% Reiterated 10.08.26on TipRanks Aug 11 07:55 −4.0%next day −3.8% · 5 days +0.2%
Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% Evercore ISI $91.00 Buy +226.4% Reiterated 09.07.26on TipRanks 09:12 −0.8%next day −1.5% · 5 days −7.7%
Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% Goldman Sachs $90.00 Buy +222.8% Reiterated 05.06.26on TipRanks Jun 3 09:15 +0.7%next day +6.4% · 5 days +4.9%
Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% Wolfe Research $88.00 Buy +215.6% Reiterated 02.06.26on TipRanks Jun 3 09:08 −8.0%next day +0.7% · 5 days +4.7%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Vera Therapeutics

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%
1 year Rami Katkhuda★★★★★★★★★★LifeSci Capital · #297
Hits 55%151 of 273 Average return +31.7%
2 years Rami Katkhuda★★★★★★★★★★LifeSci Capital · #297
Hits 55%151 of 273 Average return +31.7%

Most profitable

3 months Anupam Rama★★★★★★★★★★J.P. Morgan · #291
Hits 54%267 of 490 Average return +23.3%
1 year Anupam Rama★★★★★★★★★★J.P. Morgan · #291
Hits 54%267 of 490 Average return +23.3%
2 years Rami Katkhuda★★★★★★★★★★LifeSci Capital · #297
Hits 55%151 of 273 Average return +31.7%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $75.40 at a price of $32.29 (+133.5%); now: $69.10 at $27.88 (+147.8%).

$40.00$60.00$80.00Sep 15Oct 1Oct 15Top analysts$76.86Average target$69.10Price$27.88

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

01020301011Oct 25152Nov201Dec174Jan 26105Feb65Mar63Apr911May1341Jun2233Jul2634Aug2225Sep1523Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy91322262215
Buy143322
Hold113453
Sell000000

Earnings and sales forecast

Next report: 11.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-1.61 (from $-1.80 to $-1.39). Last quarter: $-1.52.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Vera Therapeutics
  • CEO: Marshall Fordyce
  • Employees: 361
  • 2000 Sierra Point Parkway, Brisbane, CA, 94005, US
  • veratx.com

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Data from the stock’s TipRanks forecast page, read 40 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗